Acute Lymphoblastic Leukemia: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797447
  • Drug Pipelines
  • 193 pages
  • Datamonitor Healthcare
1 of 3
The entry of CAR-T therapies will offset the generic erosion of the TKI class to drive huge growth in the acute lymphoblastic leukemia (ALL) market.

This report addresses the following questions:

- In which treatment settings are chimeric antigen receptor T-cell (CAR-T) therapies being developed and how well are they expected to perform?
- How will the current standard-of-care Gleevec fare following the launch of pipeline therapies and generic imatinib?
- What effect will generics have on key branded tyrosine kinase inhibitors (TKIs)?
- What pipeline therapies are in development for Ph-negative patients and how will they compete with Blincyto and Marqibo?
- What are the areas of highest unmet need in the ALL market?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: ACUTE LYMPHOBLASTIC LEUKEMIA

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Blincyto (blinatumomab)
- CTL0
- Gleevec (imatinib)
- Iclusig (ponatinib)
- inotuzumab ozogamicin
- JCAR0
- Marqibo (vincristine)
- Sprycel (dasatinib)
- Primary Research Methodology

TREATMENT: ACUTE LYMPHOBLASTIC LEUKEMIA

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Future Treatment

EPIDEMIOLOGY: ACUTE LYMPHOBLASTIC LEUKEMIA

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Appendix

MARKETED DRUGS: ACUTE LYMPHOBLASTIC LEUKEMIA

- Executive Summary
- Product Overview
- Product profile: Blincyto
- Product profile: Gleevec
- Product profile: Iclusig
- Product profile: Sprycel

PIPELINE: ACUTE LYMPHOBLASTIC LEUKEMIA

- Executive Summary,
- Clinical Pipeline Overview
- Appendix
- Product profile (late stage): CTL0
- Product profile (late stage): JCAR0
- Product profile (late stage): inotuzumab ozogamicin
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll